<TABLE>
First author  (year)    Pricing approaches    discussed               Country  or region  in scope
WHO   (2015)xxiv        • Mark-up  control                            Global
                        • Tax exemptions   and reductions
                        • Cost-plus pricing
                        • Internal and external reference pricing
                        • Health technology  assessments
OECD   (2008)xxv        • Mark-up  control                            OECD   countries
                        • Internal and external reference pricing
                        • Market-based   pricing
                        • Cost-plus pricing
                        • Procurement   and tendering
                        • Managed   entry agreements
Panteli et al.          • Free pricing                                15 European  countries
(2016)xxvi              • External reference pricing
                        • Internal reference pricing
                        • Value-based  pricing
                        • Negotiations  and tendering
                        • Managed   entry agreements
                        • Patient cost-sharing
Schneider  et al.       • External reference pricing                  European  countries, Brazil, Egypt,
(2017)xxvii                                                           Jordan, Kuwait, Lebanon,  Qatar,
Kavanos  et al.                                                       Saudi Arabia, South  Africa, Republic
(2017)xxviii                                                          of Korea and  the United Arab
                                                                      Emirates
Towse  et al.           • Differential pricing                        European  Union
(2015)xxix                                                            Lower-income   European   countries
Kaló et al. (2013)xxx
Clark et al. (2012)     • Tendering  and  negotiations                Global, with a focus on low- and
                                                                      middle-income   countries
</TABLE>
<UNSPECIFIED>
xxiv WHO  guideline on  country  pharmaceutical   pricing policies. Geneva: World  Health  Organization;  2015
    (http://apps.who.int/medicinedocs/documents/s21016en/s21016en.pdf,          accessed  14 November    2018).
xxv Pharmaceutical  pricing policies in a global market. Paris: Organisation  for Economic   Co-operation   and Development;
    2008  (http://www.oecd-ilibrary.org/social-issues-migration-health/pharmaceutical-pricing-policies-in-a-global-
    market_9789264044159-en,      accessed   15 November    2018)
xxvi Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt  H, Fogarty E, et al. Pharmaceutical  regulation in 15 European
    countries: A review. Health  Syst Transit. 2016;18(5):1–118.
xxvii Schneider P, Habl C, Németh  G, Primožič  S, Šebesta  R. Best practice report on external  reference pricing (ERP).
    EURIPID.  2017;2.
xxviii Kanavos P, Fontrier A-M, Gill J, Kyriopoulos D. The implementation   of external reference pricing within and  across
    country  borders. London:   London   School  of Economics;  2017  (http://www.lse.ac.uk/business-and-
    consultancy/consulting/assets/documents/the-implementation-of-external-reference-pricing-within-and-across-
    country-borders.pdf,   accessed  14 November    2018).
xxix Towse A, Pistollato M, Mestre-Ferrandiz  J, Khan Z, Kaura  S, Garrison L. European   Union  pharmaceutical   markets: a
    case for differential pricing? Int J Econ Bus. 2015;22(2):263–75.
xxx Kaló Z, Annemans   L, Garrison LP. Differential pricing of new pharmaceuticals   in lower income   European   countries.
    Expert Rev  Pharmacoeconomics      Outcomes    Res. 2013;13(6):735–41.
XL
</UNSPECIFIED>
<UNSPECIFIED>
Appendix  D: List of key publications relating to reviews of medicine pricing
</UNSPECIFIED>
<PAGE_BREAK>
